Neil H. Bander

Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line.

Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.

Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity.

A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen.

Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.

Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy.

Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy.

Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.

Antibody-based therapeutics: focus on prostate cancer.

Technology insight: monoclonal antibody imaging of prostate cancer.

Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

Active and passive immunotherapy: vaccines and antibodies.

Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2.

Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.

Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.

Editorial comment.

Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.

Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.

Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.

ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation.

Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.

89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.

Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.

Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.

Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.

Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.

Antibody-drug conjugate technology development for hematologic disorders.

Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system.

Antibody-drug conjugate target selection: critical factors.

Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture.

Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.

A prospective pilot study of (89)zr-j591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.

Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.

Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow.